NEW YORK — Precision for Medicine said today that it has acquired biospecimen providers ProMedDx and GLAS in an effort to expand its biomarker services offerings.
Norton, Massachusetts-based ProMedDx specializes in biofluid specimens, while Winston-Salem, North Carolina-based GLAS focuses on tissue-based samples, Precision for Medicine said. Specific terms of the deals were not disclosed.
"By bringing ProMedDx and GLAS into the Precision family, we are proud to offer unparalleled, global biospecimens solutions while also expanding our footprint in the exploding Massachusetts and North Carolina biotechnology sectors," Precision for Medicine President Chad Clark said in a statement.
Earlier this year, Precision for Medicine — a Bethesda, Maryland-based unit of Precision Medicine Group — acquired artificial intelligence technology developer SimplictyBio. In late 2018, the firm acquired ApoCell, which specializes in the identification and nalysis of biomarkers in both tissue and liquid biopsy.